Navigation Links
ATS Medical Announces FDA Clearance of the ATS Simulus Adjustable Annuloplasty Band

Expands Heart Valve Repair Product Portfolio

MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced FDA clearance of the ATS Simulus(R) Adjustable Annuloplasty Band.


The ATS Simulus Adjustable Annuloplasty Band is the next product in a portfolio of mitral valve repair products developed and commercialized through the Company's partnership with Genesee BioMedical.

This band respects the natural motion of the mitral annulus and its proximity to the aortic valve allowing for a safe, physiologic valve repair. The simple but elegant design of the ATS Simulus Adjustable Band allows the surgeon to make asymmetric or symmetric adjustments to the posterior segment of the mitral valve annulus at any time during the procedure, optimizing the repair. This product is also indicated for tricuspid valve repair, where a band is the preferred annuloplasty device.

Annuloplasty rings and bands are used in those cases where repair of a patient's heart valve is preferable to replacement of the valve. The ATS Simulus Adjustable Band provides additional options for surgeons in terms of different exposures, double valve procedures and minimally invasive implants.

This Simulus Adjustable Band is another product developed as a result of the collaboration between ATS and Genesee Biomedical. John Wright, PhD, CEO of GBI has been involved in heart valves and valve repair therapy for more than 25 years. Dr Wright's depth of experience has contributed significantly to the enormous growth of the Simulus product line.

Michael Dale, President and CEO of ATS Medical commented: "Our valve repair business continues to grow and build momentum. We have expanded our repair platform by adding offerings in the flexible and semi-rigid segments. The breadth of our portfolio will enable more choices for our surgeon customers to accommodate their clinical needs and that of their patients, thus bolstering our growth prospects."

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DRE Medical Equipment Releases New Multi-Function Patient Monitors
2. Discount Medical Supplies Online Store Announces New Department Dedicated to Wheelchairs and Scooters
3. EaglePicher Medical Power Announces New Li/CFx Battery Technology
4. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Celebrates Successful First Year
5. New Board Members Join American College of Medical Genetics Foundation (ACMGF): Distinguished Executive, Medical and Philanthropic Leaders Bring Additional Perspectives to the ACMGF Board
6. Optasia Medical, Ltd. Achieves ISO 9001 and ISO 13485 Certification
7. Palomar Medical to Market Quantels SINON Tattoo Removal Laser in the United States and Canada
8. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
9. AMPM to Provide Medical Billing Services for Seton Community Health Centers in Austin
10. 7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems
11. 100% Invisible Lyric(R) Hearing Aid Wins Medical Design Excellence Award
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: